Oct 21 (Reuters) - A U.S. Food and Drug Administration advisory panel on Tuesday voted 13-2 to recommend expanding approval of Vertex Pharmaceuticals Inc's cystic fibrosis drug Kalydeco to include a...
Oct 21 (Reuters) - A U.S. Food and Drug Administration advisory panel on Tuesday voted 13-2 to recommend expanding approval of Vertex Pharmaceuticals Inc's cystic fibrosis drug Kalydeco to include a wider range of patients with the rare lung disease, the company said.
The Pulmonary-Allergy Drugs Advisory Committee votes 13 - 2 in favor of a label expansion for Vertex Pharmaceuticals ' ( VRTX +3.6% ) cystic fibrosis med Kalydeco (ivacaftor) to include the R117H mutation. This expands the approved CF mutation list to ten. Post your comment!
Vertex Pharmaceuticals ( VRTX -1.5% ) will report Q3 results on October 28 after the close. The conference call will begin at 5:00 pm ET. Consensus view is a loss of ($0.63) per share on revenues of $147M. Post your comment!
By Matthew Archer : The recent announcement made by Gilead (NASDAQ: GILD ) to allow Egypt and other developing countries to develop a generic analog of its $1,000-a-day treatment for HCV may initially leave investors puzzled. However, once some important facts are revealed about the HCV virus, the
considered groundbreaking as compared to existing gene therapy; small molecule treatments - especially those developed by industry rival Vertex Pharmaceuticals . In light of recent success ProQR is considering filing an Complete Story »
Stefan Quenneville: We think [TICKER: VRTX ] Vertex Pharmaceuticals ( VRTX ) has a positive moat trend because its recent clinical success in cystic fibrosis positions it as a dominant
By Balanced Investing : Following the successful approval and launch of Incivek, Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) saw its revenue grow overnight in multiple folds in 2011. In no time, the drug crossed its
which may face some tough competition if Albuferon receives Food and Drug Administration approval. We still think Vertex's VRTX Phase II telaprevir holds the most promise among hepatitis C drugs in development. Human Genome Sciences and partner Novartis
Worldwide UTIW Vertex Pharmaceuticals VRTX Walt Disney DIS ..... UTi Worldwide Vertex Pharmaceuticals Economic Moat ..... thinks Vertex's VRTX expertise in chronic ..... Analyst Report: Vertex Pharmaceuticals Walt Disney